Clinical Trial Update: 2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating a second autologous stem cell transplant in patients with persistent or recurrent AL amyloidosis, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Al Amyloidosis
• Multiple Myeloma
• Plasma Cell Neoplasm

Snippet

Sponsor: Boston Medical Center | Conditions: Multiple Myeloma, Plasma Cell Neoplasm | Phase 2 | Status: TERMINATED | Results posted: 2017-01-27